Journal
DIAGNOSTICS
Volume 12, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/diagnostics12010013
Keywords
cardiotitinopathy; TTN truncating variants; troponin T; NT-proBNP; malignant ventricular arrhythmia; end-stage heart failure
Categories
Funding
- National Centre for Research and Development, Poland [ERA-CVD DETECTIN-HF/2/2017]
- National Science Centre, Poland [2011/01/B/NZ4/03455]
- National Institute of Cardiology, Warsaw, Poland [2.56/II/14]
Ask authors/readers for more resources
TTNtv truncating variants are a leading cause of dilated cardiomyopathy (DCM). Circulating cardiac biomarkers like hs-cTnT and NT-proBNP may not be useful for early disease detection but can assist in risk assessment. NT-proBNP levels >= 650 pg/mL are the best predictor of composite endpoints MVA and esHF in TTNtv carriers.
Titin truncating variants (TTNtv) are known as the leading cause of inherited dilated cardiomyopathy (DCM). Nevertheless, it is unclear whether circulating cardiac biomarkers are helpful in detection and risk assessment. We sought to assess 1) early indicators of cardiotitinopathy including the serum biomarkers high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in clinically stable patients, and 2) predictors of outcome among TTNtv carriers. Our single-center cohort consisted of 108 TTNtv carriers (including 70 DCM patients) from 43 families. Clinical, laboratory and follow-up data were analyzed. The earliest abnormality was left ventricular dysfunction, present in 8, 26 and 47% of patients in the second, third and fourth decade of life, respectively. It was followed by symptoms of heart failure, linked to NT-proBNP elevation and severe left ventricular systolic dysfunction, and later by arrhythmias. Hs-cTnT serum levels were increased in the late stage of the disease only. During the median follow-up of 5.2 years, both malignant ventricular arrhythmia (MVA) and end-stage heart failure (esHF) occurred in 12% of TTNtv carriers. In multivariable analysis, NT-proBNP level >= 650 pg/mL was the best predictor of both composite endpoints (MVA and esHF) and of MVA alone. In conclusion, echocardiographic abnormalities are the first detectable anomalies in the course of cardiotitinopathies. The assessment of circulating cardiac biomarkers is not useful in the detection of the disease onset but may be helpful in risk assessment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available